Friday – Clinical Track 6B Survey

Full Name(Required)
Enter your first and last names as you would like them to appear on your certificates.
Enter the email you used to register for TOXINS 2022.

Please evaluate the speakers

Topic and Speaker(s)
ExcellentGoodFairPoor
Botulinum toxin for the management of cervical dystonia: Why do patients discontinue treatment and how can we do better?
Jaroslaw Slawek, MD (Poland)
Treating pain in cervical dystonia with BoNT
Hyder (Buz) Jinnah, MD, PhD (USA)
Observations from a clinical investigator on treating cervical dystonia with a new BoNT formulation
Peter McAllister, MD (USA)
YesNo
Botulinum toxin for the management of cervical dystonia: Why do patients discontinue treatment and how can we do better?
Jaroslaw Slawek, MD (Poland)
Treating pain in cervical dystonia with BoNT
Hyder (Buz) Jinnah, MD, PhD (USA)
Observations from a clinical investigator on treating cervical dystonia with a new BoNT formulation
Peter McAllister, MD (USA)
YesNo
Botulinum toxin for the management of cervical dystonia: Why do patients discontinue treatment and how can we do better?
Jaroslaw Slawek, MD (Poland)
Treating pain in cervical dystonia with BoNT
Hyder (Buz) Jinnah, MD, PhD (USA)
Observations from a clinical investigator on treating cervical dystonia with a new BoNT formulation
Peter McAllister, MD (USA)
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care